TNX-901 is a therapeutic monoclonal antibodies designed to address significant unmet medical needs in the areas of asthma, allergy, inflammation and other diseases affecting the human immune system.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Diethylstilbestrol | Diethylstilbestrol may increase the thrombogenic activities of TNX-901. |
| Chlorotrianisene | Chlorotrianisene may increase the thrombogenic activities of TNX-901. |
| Conjugated estrogens | Conjugated estrogens may increase the thrombogenic activities of TNX-901. |
| Estrone | Estrone may increase the thrombogenic activities of TNX-901. |
| Estradiol | Estradiol may increase the thrombogenic activities of TNX-901. |
| Dienestrol | Dienestrol may increase the thrombogenic activities of TNX-901. |
| Ethinylestradiol | Ethinylestradiol may increase the thrombogenic activities of TNX-901. |
| Mestranol | Mestranol may increase the thrombogenic activities of TNX-901. |
| Estriol | Estriol may increase the thrombogenic activities of TNX-901. |
| Estrone sulfate | Estrone sulfate may increase the thrombogenic activities of TNX-901. |
| Quinestrol | Quinestrol may increase the thrombogenic activities of TNX-901. |
| Hexestrol | Hexestrol may increase the thrombogenic activities of TNX-901. |
| Tibolone | Tibolone may increase the thrombogenic activities of TNX-901. |
| Synthetic Conjugated Estrogens, A | Synthetic Conjugated Estrogens, A may increase the thrombogenic activities of TNX-901. |
| Synthetic Conjugated Estrogens, B | Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of TNX-901. |
| Polyestradiol phosphate | Polyestradiol phosphate may increase the thrombogenic activities of TNX-901. |
| Esterified estrogens | Esterified estrogens may increase the thrombogenic activities of TNX-901. |
| Zeranol | Zeranol may increase the thrombogenic activities of TNX-901. |
| Equol | Equol may increase the thrombogenic activities of TNX-901. |
| Promestriene | Promestriene may increase the thrombogenic activities of TNX-901. |
| Methallenestril | Methallenestril may increase the thrombogenic activities of TNX-901. |
| Epimestrol | Epimestrol may increase the thrombogenic activities of TNX-901. |
| Moxestrol | Moxestrol may increase the thrombogenic activities of TNX-901. |
| Estradiol acetate | Estradiol acetate may increase the thrombogenic activities of TNX-901. |
| Estradiol benzoate | Estradiol benzoate may increase the thrombogenic activities of TNX-901. |
| Estradiol cypionate | Estradiol cypionate may increase the thrombogenic activities of TNX-901. |
| Estradiol valerate | Estradiol valerate may increase the thrombogenic activities of TNX-901. |
| Biochanin A | Biochanin A may increase the thrombogenic activities of TNX-901. |
| Formononetin | Formononetin may increase the thrombogenic activities of TNX-901. |
| Estetrol | Estetrol may increase the thrombogenic activities of TNX-901. |
| Cetuximab | The risk or severity of adverse effects can be increased when Cetuximab is combined with TNX-901. |
| Human immunoglobulin G | The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with TNX-901. |
| Omalizumab | The risk or severity of adverse effects can be increased when Omalizumab is combined with TNX-901. |
| Adalimumab | The risk or severity of adverse effects can be increased when Adalimumab is combined with TNX-901. |
| Abciximab | The risk or severity of adverse effects can be increased when Abciximab is combined with TNX-901. |
| Gemtuzumab ozogamicin | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with TNX-901. |
| Indium In-111 satumomab pendetide | The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with TNX-901. |
| Infliximab | The risk or severity of adverse effects can be increased when Infliximab is combined with TNX-901. |
| Trastuzumab | The risk or severity of adverse effects can be increased when Trastuzumab is combined with TNX-901. |
| Rituximab | The risk or severity of adverse effects can be increased when Rituximab is combined with TNX-901. |
| Basiliximab | The risk or severity of adverse effects can be increased when Basiliximab is combined with TNX-901. |
| Muromonab | The risk or severity of adverse effects can be increased when Muromonab is combined with TNX-901. |
| Digoxin Immune Fab (Ovine) | The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with TNX-901. |
| Ibritumomab tiuxetan | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with TNX-901. |
| Tositumomab | The risk or severity of adverse effects can be increased when Tositumomab is combined with TNX-901. |
| Alemtuzumab | The risk or severity of adverse effects can be increased when Alemtuzumab is combined with TNX-901. |
| Capromab pendetide | The risk or severity of adverse effects can be increased when Capromab pendetide is combined with TNX-901. |
| Efalizumab | The risk or severity of adverse effects can be increased when Efalizumab is combined with TNX-901. |
| Antithymocyte immunoglobulin (rabbit) | The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with TNX-901. |
| Natalizumab | The risk or severity of adverse effects can be increased when Natalizumab is combined with TNX-901. |
| Palivizumab | The risk or severity of adverse effects can be increased when Palivizumab is combined with TNX-901. |
| Daclizumab | The risk or severity of adverse effects can be increased when Daclizumab is combined with TNX-901. |
| Bevacizumab | The risk or severity of adverse effects can be increased when Bevacizumab is combined with TNX-901. |
| Technetium Tc-99m arcitumomab | The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with TNX-901. |
| Eculizumab | The risk or severity of adverse effects can be increased when Eculizumab is combined with TNX-901. |
| Panitumumab | The risk or severity of adverse effects can be increased when Panitumumab is combined with TNX-901. |
| Ranibizumab | The risk or severity of adverse effects can be increased when Ranibizumab is combined with TNX-901. |
| Galiximab | The risk or severity of adverse effects can be increased when Galiximab is combined with TNX-901. |
| Pexelizumab | The risk or severity of adverse effects can be increased when Pexelizumab is combined with TNX-901. |
| Afelimomab | The risk or severity of adverse effects can be increased when Afelimomab is combined with TNX-901. |
| Epratuzumab | The risk or severity of adverse effects can be increased when Epratuzumab is combined with TNX-901. |
| Bectumomab | The risk or severity of adverse effects can be increased when Bectumomab is combined with TNX-901. |
| Oregovomab | The risk or severity of adverse effects can be increased when Oregovomab is combined with TNX-901. |
| IGN311 | The risk or severity of adverse effects can be increased when IGN311 is combined with TNX-901. |
| Adecatumumab | The risk or severity of adverse effects can be increased when Adecatumumab is combined with TNX-901. |
| Labetuzumab | The risk or severity of adverse effects can be increased when Labetuzumab is combined with TNX-901. |
| Matuzumab | The risk or severity of adverse effects can be increased when Matuzumab is combined with TNX-901. |
| Fontolizumab | The risk or severity of adverse effects can be increased when Fontolizumab is combined with TNX-901. |
| Bavituximab | The risk or severity of adverse effects can be increased when Bavituximab is combined with TNX-901. |
| CR002 | The risk or severity of adverse effects can be increased when CR002 is combined with TNX-901. |
| Rozrolimupab | The risk or severity of adverse effects can be increased when Rozrolimupab is combined with TNX-901. |
| Girentuximab | The risk or severity of adverse effects can be increased when Girentuximab is combined with TNX-901. |
| Obiltoxaximab | The risk or severity of adverse effects can be increased when Obiltoxaximab is combined with TNX-901. |
| XTL-001 | The risk or severity of adverse effects can be increased when XTL-001 is combined with TNX-901. |
| NAV 1800 | The risk or severity of adverse effects can be increased when NAV 1800 is combined with TNX-901. |
| Briakinumab | The risk or severity of adverse effects can be increased when Briakinumab is combined with TNX-901. |
| Otelixizumab | The risk or severity of adverse effects can be increased when Otelixizumab is combined with TNX-901. |
| AMG 108 | The risk or severity of adverse effects can be increased when AMG 108 is combined with TNX-901. |
| Iratumumab | The risk or severity of adverse effects can be increased when Iratumumab is combined with TNX-901. |
| Enokizumab | The risk or severity of adverse effects can be increased when Enokizumab is combined with TNX-901. |
| Ramucirumab | The risk or severity of adverse effects can be increased when Ramucirumab is combined with TNX-901. |
| Farletuzumab | The risk or severity of adverse effects can be increased when Farletuzumab is combined with TNX-901. |
| Veltuzumab | The risk or severity of adverse effects can be increased when Veltuzumab is combined with TNX-901. |
| Ustekinumab | The risk or severity of adverse effects can be increased when Ustekinumab is combined with TNX-901. |
| Trastuzumab emtansine | The risk or severity of adverse effects can be increased when Trastuzumab emtansine is combined with TNX-901. |
| PRO-542 | The risk or severity of adverse effects can be increased when PRO-542 is combined with TNX-901. |
| Inotuzumab ozogamicin | The risk or severity of adverse effects can be increased when TNX-901 is combined with Inotuzumab ozogamicin. |
| RI 624 | The risk or severity of adverse effects can be increased when TNX-901 is combined with RI 624. |
| Stamulumab | The risk or severity of adverse effects can be increased when TNX-901 is combined with MYO-029. |
| CT-011 | The risk or severity of adverse effects can be increased when TNX-901 is combined with CT-011. |
| Leronlimab | The risk or severity of adverse effects can be increased when TNX-901 is combined with Leronlimab. |
| Glembatumumab vedotin | The risk or severity of adverse effects can be increased when TNX-901 is combined with Glembatumumab vedotin. |
| Olaratumab | The risk or severity of adverse effects can be increased when TNX-901 is combined with Olaratumab. |
| IPH 2101 | The risk or severity of adverse effects can be increased when TNX-901 is combined with IPH 2101. |
| TB-402 | The risk or severity of adverse effects can be increased when TNX-901 is combined with TB-402. |
| Caplacizumab | The risk or severity of adverse effects can be increased when TNX-901 is combined with Caplacizumab. |
| IMC-1C11 | The risk or severity of adverse effects can be increased when TNX-901 is combined with IMC-1C11. |
| Eldelumab | The risk or severity of adverse effects can be increased when TNX-901 is combined with Eldelumab. |
| Lumiliximab | The risk or severity of adverse effects can be increased when TNX-901 is combined with Lumiliximab. |
| Canakinumab | The risk or severity of adverse effects can be increased when TNX-901 is combined with Canakinumab. |